Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Hutchison MediPharma Starts Clinical Trial of Cancer Drug

publication date: Nov 14, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Hutchison MediPharma, the drug discovery arm of Chi-Med, has begun a first-in-human Phase I clinical trial of epitinib (HMPL-813), the third of MediPharma’s oncology compounds to enter clinical testing. Epitinib is a novel, second generation, orally active, small molecule inhibitor targeting the epidermal growth factor receptor (EGFR). MediPharma hopes epitinib will prove to be effective against brain tumors that have EGFR mutations, either primary brain tumors or tumors metastasized to the brain. More details....

Stock Symbol: (AIM: HCM)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners